Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?
about
In the Pursuit of Methotrexate Treatment Response Biomarker in Juvenile Idiopathic Arthritis-Are We Getting Closer to Personalised Medicine?Cetuximab Prevents Methotrexate-Induced Cytotoxicity in Vitro through Epidermal Growth Factor Dependent Regulation of Renal Drug Transporters.Are we closer to personalized therapy in juvenile idiopathic arthritis?Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting.
P2860
Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?
@en
type
label
Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?
@en
prefLabel
Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?
@en
P2093
P2860
P356
P1476
Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?
@en
P2093
Gerd Horneff
Heinrike Schmeling
Susanne M Benseler
P2860
P2888
P304
P356
10.1038/NRRHEUM.2014.140
P407
P577
2014-08-12T00:00:00Z
P6179
1037474980